Background: Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor approved by the US Food and Drug Administration to treat crizotinib-refractory non-small cell lung cancer.
Introduction: Anaplastic lymphoma kinase (ALK) inhibitors are the mainstay treatment for patients with non-small cell lung carcinoma (NSCLC) harboring a rearrangement of the ALK gene or the ROS1 oncogenes.
Roche announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved alectinib for the treatment of people...
Introduction: Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) may derive significant clinical benefit from targeted therapies against this driver mutation ...
Press release from ESMO 2017
The FDA has accepted a new drug application (NDA) seeking the approval of ensartinib (X-396) for the treatment of adult patients with metastatic ALK-positive non–small cell lung cancer (NSCLC), according to an announcement from Xcovery Holdings
Genentech, announced that the global, randomized Phase III ALEX study met its primary endpoint and showed that Alecensa (alectinib) as...
This randomized, active controlled, multicenter phase III open-label study is designed to evaluate the efficacy and safety of alectinib compared with crizotinib treatment in participants with treatment-naive anaplastic lymphoma kinase-positive (ALK-positive) advanced non-small cell lung cancer (NSCLC).
Approximately 3-5% of patients with non-small cell lung cancer (NSCLC)belonged to anaplastic lymphoma kinase (ALK)-positive NSCLC. The treatment drugs of ALK-positive NSCLC mainly included crizotinib, ceritinib, alectinib, and brigatinib.
Genentech, announced positive results from two pivotal studies (NP28673 and NP28761) that showed alectinib, its oral investigational anaplastic lymphoma kinase...